Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
144 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05201781 | A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | recruiting | Phase 4 | 295 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | recruiting | Phase 4 | 100 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 23, 2026 | clinicaltrials |
| Lorlatinib Continuation Study |
| active not recruiting |
| Phase 4 |
| 76 |
| PfizerINDUSTRY |
| 8 |
| Sep 23, 2026 |
| clinicaltrials |
| NCT07218341 | A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 4 | 150 | Eli Lilly and CompanyINDUSTRY | 17 | Sep 22, 2026 | clinicaltrials |
| NCT00904410 | Early Assessment of the Response to Neo-adjuvant Chemotherapy in Breast Cancer Patients With FDG-PET(CHIMTEP) | completed | Phase 4 | 63 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT00911092 | Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer(COL) | completed | Phase 4 | 50 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT02584933 | Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study | active not recruiting | Phase 4 | 233 | Novartis PharmaceuticalsINDUSTRY | 21 | Sep 17, 2026 | clinicaltrials |
| NCT07072988 | Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod(OPTIMAGE) | recruiting | Phase 4 | 50 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802847 | Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.(POG) | not yet recruiting | Phase 4 | 794 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT03975829 | Pediatric Long-Term Follow-up and Rollover Study | active not recruiting | Phase 4 | 163 | Novartis PharmaceuticalsINDUSTRY | 19 | Aug 27, 2026 | clinicaltrials |
| NCT02386800 | CINC424A2X01B Rollover Protocol | active not recruiting | Phase 4 | 279 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 20, 2026 | clinicaltrials |
| NCT01742299 | Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator | completed | Phase 4 | 155 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 18, 2026 | clinicaltrials |
| NCT07766122 | Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU(ECETEP) | not yet recruiting | Phase 4 | 30 | University Hospital, ToulouseOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT01955018 | Comparison of the Ultra-low-dose Veo Algorithm With the Gold Standard Filtered Back Projection for Detecting Pulmonary Asbestos-related Conditions | completed | Phase 4 | 90 | University Hospital, Clermont-FerrandOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT00333099 | INEC Study: Immuno-modulating Enteral Nutrition in Cancer | completed | Phase 4 | 250 | University Hospital, Clermont-FerrandOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT00756509 | Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib | completed | Phase 4 | 34 | Novartis PharmaceuticalsINDUSTRY | 5 | Jul 16, 2026 | clinicaltrials |
| NCT04846855 | Regional Anesthesia for Totally Awake Upper Limb Surgery in PEDiatric Population(RATAPED) | completed | Phase 4 | 100 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07028125 | Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma(CANIQOL) | recruiting | Phase 4 | 83 | Centre Francois BaclesseOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT04877522 | Asciminib Roll-over Study | recruiting | Phase 4 | 347 | Novartis PharmaceuticalsINDUSTRY | 29 | Jul 6, 2026 | clinicaltrials |
| NCT03706157 | Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE(CineDoxo) | completed | Phase 4 | 10 | University Hospital, Strasbourg, FranceOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05803941 | Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | recruiting | Phase 4 | 700 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 4, 2026 | clinicaltrials |
| NCT04460235 | Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma(HEMATOVAC) | recruiting | Phase 4 | 160 | Poitiers University HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT03610022 | Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1(OPTIVISMO-1) | completed | Phase 4 | 27 | University Hospital, BordeauxOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07195344 | Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.(TDXdose) | recruiting | Phase 4 | 210 | Institut Claudius RegaudOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06646471 | PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies(PROMETHEE) | recruiting | Phase 4 | 500 | GFPC InvestigationOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT01574170 | Prospective Construction and Validation of a Prognostic Score to Identify Among Patients With Metastatic Breast Cancer Those Who Benefit From a Third Line Chemotherapy in Terms of Overall Survival(METAL3) | completed | Phase 4 | 267 | Institut Claudius RegaudOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT01127295 | Pharmacology of Adjuvant Hormonotherapy in Breast Cancer(PHACS) | completed | Phase 4 | 2,000 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT01553903 | Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not(OXYTAM) | completed | Phase 4 | 29 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT01612871 | Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer(MIRHO) | completed | Phase 4 | 39 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03514381 | Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma(IPIAP-STM) | completed | Phase 4 | 59 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05203172 | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | recruiting | Phase 4 | 46 | PfizerINDUSTRY | 17 | Apr 7, 2026 | clinicaltrials |
| NCT02555748 | Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma(SUP-R) | completed | Phase 4 | 47 | Institut Claudius RegaudOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06876649 | A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib | recruiting | Phase 4 | 787 | Eli Lilly and CompanyINDUSTRY | 8 | Mar 2, 2026 | clinicaltrials |
| NCT06876662 | A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma | recruiting | Phase 4 | 279 | Eli Lilly and CompanyINDUSTRY | 8 | Mar 2, 2026 | clinicaltrials |
| NCT04813913 | VASCular Impact of Angiogenic Treatment in Patients With Advanced Colorectal Cancer(VASCATAQ) | completed | Phase 4 | 13 | University Hospital, RouenOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03673332 | Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies(EPITOP-01) | terminated | Phase 4 | 40 | Institut Paoli-CalmettesOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04373564 | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years(ODYSSEY) | recruiting | Phase 4 | 2,076 | GuerbetINDUSTRY | 8 | Jan 22, 2026 | clinicaltrials |
| NCT04952766 | Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults(EREVA) | completed | Phase 4 | 196 | Centre Hospitalier Régional d'OrléansOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT02651948 | Transperineal, MRI-guided, Prostate Biopsy | completed | Phase 4 | 90 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT06717919 | HOPE Against Cancer Recurrence in HCC(HOPE4Cancer) | recruiting | Phase 4 | 220 | Philipp DutkowskiOTHER | 17 | Dec 16, 2025 | clinicaltrials |
| NCT02485860 | Interest in the Use of Dressings With Honey for Wound Healing After Excision of Pilonidal Cyst(Pilomiel) | completed | Phase 4 | 890 | Centre Hospitalier Departemental VendeeOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT03963206 | Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)(CLERANCE) | completed | Phase 4 | 110 | Hospices Civils de LyonOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT03229200 | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | active not recruiting | Phase 4 | 297 | Pharmacyclics Switzerland GmbHINDUSTRY | 17 | Oct 30, 2025 | clinicaltrials |
| NCT02558504 | Radiofrequency in the Treatment of Barrett's Oesophagus(HARMONI) | completed | Phase 4 | 87 | Hospices Civils de LyonOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04319198 | Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy | completed | Phase 4 | 25 | Gilead SciencesINDUSTRY | 3 | Sep 30, 2025 | clinicaltrials |
| NCT06934057 | Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma(CABOLD) | recruiting | Phase 4 | 50 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT00370240 | Chlorhydrate of Ropivacaine and Breast Cancer Surgery | completed | Phase 4 | 260 | Institut CurieOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT04827030 | ER-One: A Double-blind Trial of Erector Spinae Block (ESP) Versus Paravertebral Block (PVB) Before Breast Cancer Surgery(ER-One) | completed | Phase 4 | 292 | Institut CurieOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT00646945 | Study of the Efficacy of Kalinox® 170 Bar in Adult Oncology | completed | Phase 4 | 204 | Air Liquide Santé InternationalINDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
Data updated 4 days agoSource updated unknownsource: clinicaltrials